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Background: Proton beam therapy (PBT) is effective in the treatment of iris melanoma. 
Reported complications after PBT are radiation-induced cataract and raised intraocular pressure 
(IOP). Filtering glaucoma surgery has generally been avoided because of fears of seeding.
Case report: A 37-year-old man presented with a self-discovered, pigmented lesion on his 
right iris. Four years later, the pigmented lesion was diagnosed as an iris melanoma, because of 
documented growth. The patient was treated with PBT but developed secondary glaucoma one 
month later. The IOP could not be controlled despite maximal medical therapy and selective 
laser trabeculoplasty (SLT). Finally, Baerveldt implant surgery was performed, resulting in an 
IOP lowering to 10 mmHg and stabilization of the glaucomatous visual field loss.
Conclusion: Our case demonstrates that Baerveldt implant surgery is a reasonable therapy for 
glaucoma following successful radiotherapy of iris melanoma.
Keywords: iris melanoma, proton beam therapy, secondary glaucoma, Baerveldt implant 
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Introduction
Iris melanoma comprises 3% to 10% of all uveal melanomas and is the most common 
primary malignancy of the iris.1,2 It tends to have a ten-year metastasis rate of 3% to 
6%.1–3 Possible therapies for iris melanoma include iridectomy, iridocyclectomy, plaque 
brachytherapy, proton beam therapy (PBT), and enucleation. PBT is generally selected 
if the tumor is too extensive for surgical excision or if such surgery is rejected because 
the surgical iris coloboma is expected to cause unacceptable photophobia or cosmetic 
deficit. The main complications after PBT are radiation-induced cataract and raised IOP. 
Trabecular scarring may play a role in the latter.4 Secondary glaucoma occurs in 7% of 
eyes with untreated iris melanoma and in 30% of patients with microscopically-confirmed 
iris melanoma, occurring mostly because of tumor infiltration of the trabecular meshwork 
with outflow obstruction.5,6 Traditionally, filtering glaucoma surgery has been avoided in 
patients with iris melanoma because of fears that such aqueous drainage might encourage 
subconjunctival or intraorbital tumor seeding.2,3 Nevertheless, insights into the biology 
of uveal melanomas and outcome studies after PBT encouraged us to treat a patient with 
a Baerveldt tube implantation because of rapidly deteriorating vision and uncontrollable 
glaucoma.
Case report
A 37-year-old man discovered a pigmented iris lesion in his right eye. The best-
corrected visual acuity (BCVA) was 6/6. Ophthalmologic examination showed a Clinical Ophthalmology 2010:4 408
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to 13 mmHg. After one year of follow-up, the IOP was 
stable at 10 mmHg with the additional use of dorzolamide 
and timolol. The visual field showed no further deteriora-
tion. The BCVA was 6/15. The patient declined systemic 
screening for metastasis; however, he remains under intensive 
ophthalmic surveillance.
Discussion
Secondary glaucoma after PBT for iris melanoma can be 
difficult to control with medical therapy.7 We report success-
ful lowering of the IOP in such a case by using a Baerveldt 
glaucoma implant.
To our knowledge this approach has not been reported 
previously. As a rule, drainage surgery is avoided after 
treatment of iris melanoma, probably because of concerns 
that tumor cells might seed through the drainage fistula 
and metastasize to other parts of the body. Therefore, we 
initially attempted to lower the IOP by SLT. Insights from 
genetic studies on uveal melanomas suggest, however, that 
these tumors metastasize almost exclusively if they show 
loss of chromosome 38 or class II gene expression profile.9 
There is growing evidence that metastasis starts at a very 
early stage, before the patient even presents to the ophthal-
mologist.10 For these reasons, there are now considerable 
doubts that glaucoma drainage surgery would enhance risks 
of metastasis spread to the rest of the body by providing an 
exit route from the eye.
Another concern is that the iris melanoma can recur and 
seed through the tube into the subconjunctival and orbital 
tissues. We consider these risks to be small, firstly, because 
local tumor recurrence is rare after PBT and, secondly, 
because the tumor was located far from the internal opening 
of the tube (Figure 1d). In any case, the patient is being moni-
tored closely so that appropriate treatment can be adminis-
tered without delay in case of re-growth of the tumor.
pigmented iris lesion between the 5.30 and 6.30 o’clock 
meridians with a basal diameter of 3.5 mm and a thickness 
of 1.4 mm. Gonioscopy showed pigment deposition in the 
inferior and nasal parts of the iridocorneal angle. The IOP 
was 25 mmHg. Ultrasonography showed no involvement of 
the ciliary body. The left eye was normal. Initially, the tumor 
showed no growth; however, four years after presentation, the 
iris lesion had changed to a diffuse tumor, extending from 
the 4.30 to 6.30 o’clock meridians with seeding onto the iris 
surface from the 3.30 to 7.00 o’clock meridians. The pupil 
also became oval (Figure 1a). Gonioscopy showed pigment 
deposition in the iridocorneal angle between the 1.00 and 
10.00 o’clock meridians. The BCVA decreased to 6/7.5. 
The patient refused a biopsy for histological examination. 
Because of documented growth, the tumor was diagnosed 
as an iris melanoma.
The entire anterior segment was treated with PBT 
(53.1 Gy, administered in four fractions over four days). 
One month later (Figures 1b and 1c) the patient developed 
secondary glaucoma with IOP levels fluctuating between 20 
and 43 mmHg, despite maximal medical therapy. The optic 
disc showed normal cupping.
SLT was performed, placing 25 shots with a total energy 
of 15 mJ in the nasal quadrant. The IOP decreased slightly but 
only transiently. Further treatment of the temporal quadrant 
did not lead to a reduction of IOP. Meanwhile, the optic disc 
cupping had become pathological and glaucomatous visual 
field loss had progressed from mild loss to very extensive 
loss within two months.
Since the patient was keen to preserve the remaining 
vision in this eye, despite advice about a possible risk of 
extraocular spread, we finally placed a Baerveldt tube in the 
anterior chamber (Figure 1d and Figure 2). The IOP decreased 
Figure 1 Slit lap figures. Figure 1a shows the iris lesion when diagnosed as iris 
  melanoma. Figure 1b shows the lesion after PBT. Figure 1c shows the lesion after PBT. 
Figure 1d shows the Baerveldt tube in the temporal/superior quadrant.
Figure 2 A Visante OCT scan showing the Baerveldt tube in the anterior chamber 
to the left.Clinical Ophthalmology 2010:4
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Further studies with more patients and long-term 
  follow-up are indicated to evaluate the safety and efficacy of 
the Baerveldt glaucoma implant for the treatment of second-
ary glaucoma after PBT for iris melanoma.
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